Vestal Point Capital, LP Astria Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.32 Trillion
- Q3 2024
A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 4,000,000 shares of ATXS stock, worth $36.6 Million. This represents 3.34% of its overall portfolio holdings.
Number of Shares
4,000,000
Previous 3,250,000
23.08%
Holding current value
$36.6 Million
Previous $29.6 Billion
48.91%
% of portfolio
3.34%
Previous 2.21%
Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
107Shares Held
48.6MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$59.3 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$46.7 Million0.78% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$32.5 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$32.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.46MShares$31.6 Million3.94% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $139M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...